CAPTRUST Financial Advisors
LUCD icon

CAPTRUST Financial Advisors’s Lucid Diagnostics LUCD Stock Holding History

CAPTRUST Financial Advisors’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.5K Buy
+15,440
New +$16.6K ﹤0.01% 3216
2022
Q3 		– Sell
-1,421
Closed -$3K – 3194
2022
Q2 		$3K Buy
+1,421
New +$3.16K ﹤0.01% 4310

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

CAPTRUST Financial Advisors's LUCD Position: Q2 2026 in Review

CAPTRUST Financial Advisors opened a new position in Lucid Diagnostics (LUCD) in Q2 2026: 15,440 shares worth $16.5K. The stake represents ﹤0.01% of the portfolio and ranks #3216 among its holdings. This is a return to the name: CAPTRUST Financial Advisors previously reported a position in LUCD as recently as Q2 2022.

CAPTRUST Financial Advisors first reported a position in LUCD in Q2 2022 and has held it in 2 quarters since. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • CAPTRUST Financial Advisors held 15,440 shares of Lucid Diagnostics worth $16.5K as of Q2 2026.
  • Lucid Diagnostics was a new CAPTRUST Financial Advisors position in Q2 2026.
  • Lucid Diagnostics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #3216 holding.
  • CAPTRUST Financial Advisors first reported a position in Lucid Diagnostics in Q2 2022 and has held it in 2 quarters since.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.